Skip to Main Content
Table 1—

Effect of 4-week treatment with placebo or NVP DPP728 at 100 mg t.i.d. or 150 mg b.i.d. in subjects with type 2 diabetes on body weight, fasting and prandial glucose, and insulin and lipid levelslegend

Placebo (n = 32)NVP DPP728
100 mg t.i.d. (n = 30)150 mg b.i.d. (n = 30)
Body weight (kg) Baseline 82.6 ± 2.4 79.9 ± 2.0 77.9 ± 2.0 
 Change −0.2 ± 0.3 0.1 ± 0.3 −0.1 ± 0.3 
24-h plasma glucose (mmol/l) Baseline 9.2 ± 0.3 8.9 ± 0.3 8.8 ± 0.3 
 Change −0.1 ± 0.1 −1.1 ± 0.1* −1.0 ± 0.1* 
24-h plasma insulin (pmol/l) Baseline 157 ± 12 157 ± 13 153 ± 15 
 Change 16 ± 8 −9 ± 8 −9 ± 8 
FPG (mmol/l) Baseline 8.7 ± 0.2 8.5 ± 0.3 8.5 ± 0.3 
 Change 0.1 ± 0.2 −0.9 ± 0.2* −0.6 ± 0.2 
Glucose excursion§ (mmol/l) Baseline 4.1 ± 0.3 3.9 ± 0.2 4.1 ± 0.3 
 Change −0.1 ± 0.2 −1.2 ± 0.2* −1.3 ± 0.2* 
Prandial glucose (mmol/l per h) Baseline 6.0 ± 0.8 4.8 ± 0.7 5.5 ± 0.7 
 Change −0.0 ± 0.6 −2.8 ± 0.6* −3.0 ± 0.6* 
Fasting insulin (pmol/l) Baseline 79 ± 6 81 ± 8 78 ± 7 
 Change 4 ± 5 −1 ± 5 5 ± 0 
Insulin-to-glucose excursion rate (pmol/mmol) Baseline 12.6 ± 0.9 16.2 ± 1.7 15.9 ± 2.8 
 Change 1.7 ± 0.8 3.6 ± 2.0 7.4 ± 2.1 
Total cholesterol (mmol/l) Baseline 5.8 ± 1.0 5.7 ± 0.8 5.5 ± 0.9 
 Change 0.1 ± 0.1 −0.2 ± 0.17 −0.2 ± 0.1 
HDL cholesterol (mmol/l) Baseline 1.3 ± 0.5 1.3 ± 0.3 1.3 ± 0.3 
 Change 0.01 ± 0.03 0.03 ± 0.03 0.02 ± 0.03 
LDL cholesterol (mmol/l) Baseline 3.7 ± 0.9 3.6 ± 0.8 3.5 ± 0.8 
 Change 0.02 ± 0.09 −0.17 ± 0.08 −0.18 ± 0.09 
VLDL cholesterol (mmol/l) Baseline 0.35 ± 0.15 0.32 ± 0.16 0.32 ± 0.14 
 Change 0.03 ± 0.02 −0.02 ± 0.02 −0.01 ± 0.02 
Triglycerides (mmol/l) Baseline 1.7 ± 0.7 1.7 ± 1.1 1.6 ± 0.7 
 Change 0.14 ± 0.09 −0.14 ± 0.09 −0.09 ± 0.09 
Placebo (n = 32)NVP DPP728
100 mg t.i.d. (n = 30)150 mg b.i.d. (n = 30)
Body weight (kg) Baseline 82.6 ± 2.4 79.9 ± 2.0 77.9 ± 2.0 
 Change −0.2 ± 0.3 0.1 ± 0.3 −0.1 ± 0.3 
24-h plasma glucose (mmol/l) Baseline 9.2 ± 0.3 8.9 ± 0.3 8.8 ± 0.3 
 Change −0.1 ± 0.1 −1.1 ± 0.1* −1.0 ± 0.1* 
24-h plasma insulin (pmol/l) Baseline 157 ± 12 157 ± 13 153 ± 15 
 Change 16 ± 8 −9 ± 8 −9 ± 8 
FPG (mmol/l) Baseline 8.7 ± 0.2 8.5 ± 0.3 8.5 ± 0.3 
 Change 0.1 ± 0.2 −0.9 ± 0.2* −0.6 ± 0.2 
Glucose excursion§ (mmol/l) Baseline 4.1 ± 0.3 3.9 ± 0.2 4.1 ± 0.3 
 Change −0.1 ± 0.2 −1.2 ± 0.2* −1.3 ± 0.2* 
Prandial glucose (mmol/l per h) Baseline 6.0 ± 0.8 4.8 ± 0.7 5.5 ± 0.7 
 Change −0.0 ± 0.6 −2.8 ± 0.6* −3.0 ± 0.6* 
Fasting insulin (pmol/l) Baseline 79 ± 6 81 ± 8 78 ± 7 
 Change 4 ± 5 −1 ± 5 5 ± 0 
Insulin-to-glucose excursion rate (pmol/mmol) Baseline 12.6 ± 0.9 16.2 ± 1.7 15.9 ± 2.8 
 Change 1.7 ± 0.8 3.6 ± 2.0 7.4 ± 2.1 
Total cholesterol (mmol/l) Baseline 5.8 ± 1.0 5.7 ± 0.8 5.5 ± 0.9 
 Change 0.1 ± 0.1 −0.2 ± 0.17 −0.2 ± 0.1 
HDL cholesterol (mmol/l) Baseline 1.3 ± 0.5 1.3 ± 0.3 1.3 ± 0.3 
 Change 0.01 ± 0.03 0.03 ± 0.03 0.02 ± 0.03 
LDL cholesterol (mmol/l) Baseline 3.7 ± 0.9 3.6 ± 0.8 3.5 ± 0.8 
 Change 0.02 ± 0.09 −0.17 ± 0.08 −0.18 ± 0.09 
VLDL cholesterol (mmol/l) Baseline 0.35 ± 0.15 0.32 ± 0.16 0.32 ± 0.14 
 Change 0.03 ± 0.02 −0.02 ± 0.02 −0.01 ± 0.02 
Triglycerides (mmol/l) Baseline 1.7 ± 0.7 1.7 ± 1.1 1.6 ± 0.7 
 Change 0.14 ± 0.09 −0.14 ± 0.09 −0.09 ± 0.09 
legend

Data are means ± SEM.

*

P < 0.001;

P < 0.05 versus placebo;

P < 0.05;

§

glucose excursion = difference between maximum glucose in the 4-h postbreakfast period minus mean of prebreakfast glucose;

prandial glucose = area under the 4-h plasma glucose curve after breakfast;

peak Δ postprandial insulin divided by peak Δ postprandial glucose after breakfast.

Close Modal

or Create an Account

Close Modal
Close Modal